Yi-Long Wu

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Yi-Long Wu
Nov 12, 2024, 19:34 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 24, 2024, 20:21 | Insight
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 3
Hidehito Horinouchi shared on X: Advancing Multimodal Therapies in Stage III NSCLC Chairs: Feng-Ming Spring Kong,…
Aug 14, 2024, 01:53 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 6, 2024, 06:07 | Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Aug 5, 2024, 01:55 | Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 30, 2024, 13:41 | Insight
Brendon Stiles: Neoadjuvant chemo-ICI in marginally resectable patients
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Jul 30, 2024, 06:39 | Insight
Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC
Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et…
Jul 27, 2024, 14:16 | Insight
Foritinib in advanced ROS1-rearranged NSCLC in China
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jul 16, 2024, 13:55 | Blog
5 papers to read suggested by Vivek Subbiah
We are presenting articles suggested by Vivek Subbiah: 1.'Pancreatic Cancer Surveillance and Survival of High-Risk…
May 19, 2024, 05:07 | Drugs
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science
Top Science shared on X: “This is the first prospective phase 2 study to directly…
May 7, 2024, 15:08 | Blog
Stephen Liu: Dr. Yi-Long Wu discusses adjuvant EGFR targeted therapy at RomeLung24
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: "Dr.…
May 3, 2024, 20:15 | Opinion
Brendon Stiles: Great presentation from Dr. Wu on ALINA
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Apr 26, 2024, 20:26 | Insight
New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial
Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial Authors:…
Apr 23, 2024, 23:18 | Insight
Karan Sood: A much needed asian perspective on thoracic oncology
Karan Sood, Medical Oncology Resident at Jawaharlal Nehru Medical College, shared on X: “In company…
Apr 19, 2024, 15:52 | Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Oct 23, 2023, 15:35 | Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
All: 16 Posts: 1 - 100
Special Coverage